Table 1.
Patient and Donor Characteristics at Transplantation
| No PT-Cy (n = 195) | PT-Cy (n = 136) | p Value | |
|---|---|---|---|
| Recipient age, yrs | 56 [16–76] | 53 [15–76] | 0.11 |
| Male/female | 114 (58)/81 (42) | 86 (63)/50 (37) | 0.38 |
| Diagnosis | 0.040 | ||
| Acute myeloid leukemia | 83 (43) | 70 (51) | |
| Acute lymphoblastic leukemia | 32 (16) | 17 (13) | |
| Lymphoma | 21 (11) | 23 (17) | |
| Multiple myeloma | 4 (2) | 4 (3) | |
| Myelodysplastic syndrome | 22 (11) | 13 (10) | |
| Myeloproliferative neoplasm | 33 (17) | 9 (7) | |
| Disease status at transplantation | 0.31 | ||
| Complete remission | 95 (49) | 74 (54) | |
| Active or progressive disease or partial response | 100 (51) | 62 (46) | |
| Disease risk index | 0.007 | ||
| Low and intermediate | 151 (77) | 87 (64) | |
| High and very-high | 44 (23) | 49 (36) | |
| Karnofsky index ≤80% | 27 (14) | 25 (18) | 0.26 |
| Comorbidity index ≥3 | 54 (28) | 27 (20) | 0.25 |
| Cardiovascular risk factors | |||
| None | 31 (16) | 24 (18) | 0.67 |
| Male >50 yrs of age or female >60 yrs of age | 110 (56) | 62 (46) | 0.05 |
| Obesity | 32 (16) | 12 (9) | 0.045 |
| Hypertension | 30 (15) | 22 (16) | 0.73 |
| Dyslipidemia | 23 (12) | 7 (5) | 0.038 |
| Smoking∗ | 55 (28) | 37 (27) | 0.84 |
| Diabetes | 17 (9) | 8 (6) | 0.34 |
| Cardiac event before HSCT | 45 (23) | 27 (20) | 0.48 |
| Left ventricular systolic dysfunction | 21 (11) | 10 (7) | 0.30 |
| Exposure to Cy before HSCT | 34 (17) | 32 (24) | 0.17 |
| Cumulative Cy dose before HSCT, mg/kg | |||
| Median [Q1–Q3] | 97.5 [59.5–128] | 134.4 [87.1–--172.5] | 0.030 |
| Missing data | 4 (2) | 4 (2) | |
| Exposure to anthracyclines before HSCT | 113 (68) | 108 (79) | 0.024 |
| Cumulative anthracyclines dose before HSCT, mg/m2 | 0.028 | ||
| Median [Q1–Q3] | 38.7 [0–63.6] | 38.7 [22.5–64.5] | |
| Missing data | 5 (3) | 3 (2) | |
| Previous autologous HSCT | 16 (8) | 16 (12) | 0.28 |
| Previous allogeneic HSCT | 4 (2) | 16 (12) | <0.001 |
| Donor | <0.001 | ||
| HLA-identical sibling | 83 (42.5) | 6 (4) | |
| Matched-unrelated | 111 (57) | 13 (10) | |
| Haploidentical | 1 (0.5) | 117 (86) | |
| Conditioning regimen | <0.001 | ||
| Myeloablative | 99 (51) | 32 (23.5) | |
| Reduced intensity | 39 (20) | 46 (34) | |
| Sequential | 57 (29) | 58 (42.5) | |
| Graft source | <0.001 | ||
| Peripheral blood stem cell | 192 (98) | 111 (82) | |
| Bone marrow | 3 (2) | 25 (18) | |
| ATG | 194 (99.5) | 118 (87) | < 0.001 |
| PT-Cy | |||
| 1 day | 0 (0) | 33 (24) | |
| 2 days | 0 (0) | 103 (76) | |
Values are median [range or Q1–Q3, 25th and 75th percentile] or n (%) unless otherwise indicated.
ATG = antithymocyte globulin; Cy = cyclophosphamide; HLA = human leukocyte antigen; HSCT = hematopoietic stem cell transplantation; PT-Cy = post-transplant cyclophosphamide.
∗
Smoking was defined as ever regular smoker, occasional smoker, or ex-smoker, and it was compared with never smoker.